Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.14

    ▲ −9.00 (−0.98%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Impact Healthcare REIT — Accretive acquisitions and attractive financing

Care REIT (LSE: CRT)

Last close As at 05/08/2026

GBP1.08

— 0.00 (0.00%)

Market capitalisation

—

More on this equity

Research: Real Estate

Impact Healthcare REIT — Accretive acquisitions and attractive financing

Late in 2021 Impact Healthcare REIT (IHR) announced significant investment activity amounting to £52m and its debut transaction in the institutional debt market. The investments are accretive to earnings and the new long-term fixed rate debt is attractively priced, reflecting lender confidence in the robustness of the business model, and provides a good match to IHR’s long-term income profile.

Written by

Martyn King

Director, Financials. Property and Insurance

Real Estate

Impact Healthcare REIT

Accretive acquisitions and attractive financing

Business update

Real estate

12 January 2022

Price

118p

Market cap

£414m

Gross debt (£m) at 30 September 2021

67.5

Gross LTV at 30 September 2021

14.5%

Shares in issue

350.6m

Free float

90.6%

Code

IHR

Primary exchange

LSE

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(0.5)

3.9

8.9

Rel (local)

(2.7)

(0.4)

(1.5)

52-week high/low

122p

108p

Business description

Impact Healthcare REIT, traded on the Main Market of the London Stock Exchange, invests in a diversified portfolio of UK healthcare assets, primarily residential and nursing care homes, let on long leases to high-quality operators. It aims to provide shareholders with attractive and sustainable returns, primarily in the form of dividends, underpinned by structural growth in demand for care.

Next events

Q421 NAV update

Expected late January 2022

FY21 results

March 2022

Analyst

Martyn King

+44 (0)20 3077 5745

Impact Healthcare REIT is a research client of Edison Investment Research Limited

Late in 2021 Impact Healthcare REIT (IHR) announced significant investment activity amounting to £52m and its debut transaction in the institutional debt market. The investments are accretive to earnings and the new long-term fixed rate debt is attractively priced, reflecting lender confidence in the robustness of the business model, and provides a good match to IHR’s long-term income profile.

Year end

Net rental income (£m)

EPRA
earnings* (£m)

EPRA
EPS* (p)

EPRA NAV/
share (p)

DPS
(p)

P/NAV/
share** (x)

Yield**
(%)

12/19

24.0

17.6

6.9

106.8

6.17

1.11

5.2

12/20

30.8

23.1

7.3

109.6

6.29

1.08

5.3

12/21e

36.4

27.5

8.5

112.3

6.41

1.05

5.4

12/22e

41.4

33.5

9.6

116.9

6.57

1.01

5.6

Note: *EPRA earnings exclude fair value movements on properties and interest rate derivatives. **P/NAV and yield are based on the current share price.

Converting a strong investment pipeline

IHR has completed the £3.25m acquisition (before costs) of an established care home at a 7.5% gross yield and exchanged contracts for the £11.0m (before costs) acquisition of two established homes in Northern Ireland at a 7.8% gross yield. It has also invested £37.5m in a portfolio of 12 established homes, initially by way of a loan to an existing tenant, which has been able to take immediate operational control of the homes pending the completion of a potentially lengthy regulatory approval process. Once this process completes, we expect IHR to exercise its purchase option to acquire the homes at a 7.2% gross yield. Meanwhile, the loan earns interest at a similar level (net of tax). The £75m of new institutional debt is attractively priced at 2.97% with a weighted average maturity of 14 years. It provides additional debt capacity to pursue a continuing strong investment pipeline and locks in a positive spread compared with IHR’s income profile.

Core income with asset management potential

Driven by demographics rather than the economy, a growing elderly population and a shortage of quality care homes suggests a strong demand in years to come. IHR’s business model is built around long-term partnerships with a growing list of selected tenant operators, investing alongside them in suitable properties that they can operate efficiently, providing a good quality of care, to sustain a growing stream of long-term rental income. Its portfolio comprises a majority of core, good-quality, upper middle-market homes alongside value-add assets where, working in partnership with tenants, there is potential to upgrade/extend facilities and reposition homes in their local markets. Asset management benefits residents and operators and offers enhanced returns on a pure ‘buy-and-hold’ strategy.

Valuation: Robust, indexed, long-term income

FY21e DPS represents an attractive yield of 5.4%, with strong prospects for fully covered dividend growth (on both an EPRA basis and an adjusted ‘cash’ basis) from acquisitions and predominantly RPI-indexed rent uplifts. This supports a c 6% premium to Q321 NAV per share, similar to the average since IPO.

Further details

Significant acquisition progress

In late December 2021, IHR announced a total investment of £52m in 15 care homes (including a portfolio of 12 homes), in each case allowing it to grow with existing tenants. The transactions comprise:

■

The completed acquisition of Springhill Nursing care home in Kilmarnock, Scotland for £3.25m (before costs) in a sale and leaseback transaction with existing tenant, Silverline, which now operates four IHR-owned homes.1 The home is a four-storey Georgian building with a substantial purpose-built extension offering 61 beds with en suite wet room facilities. The initial rent is £243k pa, a 7.5% gross yield on the consideration, with a fixed lease term of 25 years, no break clauses and annual RPI uplifts, capped and collared between 2% and 4%.

IHR’s first transaction with Silverline was in March 2020, when it acquired three homes.

■

The exchange of contracts for the acquisition of two care homes in Northern Ireland for an aggregate £11.0m (before costs), subject to re-registration by the local regulator,2 expected to be procedural. The homes, one in north-west Belfast and one in the coastal town of Larne, provide a combined 147 en suite bedrooms and will be operated by Electus, an existing tenant. On completion, this will take IHR’s total number of homes in Northern Ireland to five, all operated by Electus.3 The Northern Irish investment market is somewhat less competitive than elsewhere in the UK and yields are typically higher. The initial rent is £855k pa, a 7.8% gross yield on the consideration, with a fixed lease terms of 25 years with no break clauses and annual RPI uplifts, capped and collared between 2% and 4%.

The Northern Irish regulator is the Regulation and Quality Improvement Authority.

IHR’s first transaction with Electus was in December 2020 when it acquired three homes.

■

An initial investment of £37.5m in a portfolio of 12 care homes in Fife, Scotland, providing 480 high-quality en suite beds within established residential areas. The structure of this transaction initially appears complex, although we expect it will ultimately result in IHR taking direct ownership of the homes, which will be let to Holmes Care Group, an existing tenant. IHR’s initial investment has been made by way of a loan to Holmes, allowing it to complete the acquisition of the previous owner/occupier, Kingdom Homes, whose owners are retiring. By this route, Holmes has taken immediate operational control of the homes, avoiding a potentially lengthy transition period while regulatory approvals4 are sought to register the homes in new legal entities. IHR has the option to acquire the property assets5 once the regulatory approvals have been received, later in 2022, and we expect it to do so. Meanwhile, IHR will receive interest payments on the loan at 8.6% pa,6 generating immediate income. The loan has been structured to include protections for IHR’s shareholders, including security over the homes and operational covenants. New 30-year leases have been pre-agreed, on IHR’s standard terms, with an initial rent of £2.7m, reflecting a gross initial yield of 7.2%. The transaction includes an additional £2.5m deferred payment, subject to the future performance of the homes that, if payable, will result in increased rental payments.

Scottish homes are regulated by the Care Inspectorate.

Holmes also has the option to sell the property assets to IHR. Both options allow IHR to fix the future price of the property assets and rents in advance.

Interest received by IHR is taxable under UK REIT tax rules. On a net basis the loan interest is similar to future rental income.

Assuming the exercise of options on the Holmes acquisition and completion of the assets where contracts have been exchanged, IHR’s portfolio would increase to 124 properties with an annualised rent roll of more than £38m.

IHR reports a continuing strong investment pipeline.

New long-term institutional debt

The £75m of new long-term institutional debt represents IHR’s first transaction in the institutional debt market. It comprises two tranches at a blended average rate of 2.97%7 and a weighted average maturity of 14 years. The terms are attractive and IHR attributes this to the resilience of its strategy and the performance of its tenants during the pandemic. The first tranche (£37m) was drawn in late December 2021 and the second tranche (£38m) will be drawn in June 2022. The long-term, fixed-rate nature of the debt locks in a positive spread compared with IHR’s income profile and this spread should increase as rental income increases with inflation. IHR’s total weighted average debt maturity has increased to 4.7 years and will increase as the second tranche is drawn.

£37m at 2.932% and £38m at 3.002%, both maturing in 2035.

Most of the proceeds will be used to fund the growth in the portfolio, including the transactions detailed above, while £10m has been used to cancel a portion of the group’s revolving credit facilities.

Forecast changes

IHR continued to trade well in the three months ending 30 September 2021 (Q321) with the portfolio performing as expected and rents continuing to be collected in full. NAV per share increased to 111.82p (H121: 110.66p) and including DPS paid, the NAV total return was 2.5% bringing the total return in the first nine months of FY21 to 8.5%. Income and capital values both benefitted from continuing inflation-linked rental growth, with an average 3.79% uplift was achieved on completed reviews in the quarter. Like-for-like growth in total portfolio property valuations was 1.4%, further benefiting from valuation yield compression (end-Q321 net initial yield of 6.67% compared with 6.75% at end-H121).

Exhibit 1 shows the relatively modest changes to our forecasts, extended to FY23. FY21 is slightly reduced by the timing of acquisitions, more than made up for in FY22 by an increased acquisition assumption, with growth continuing in FY23, including a full-year contribution from FY22 acquisitions.

Exhibit 1: Summary of key forecast data

New forecasts

Old forecasts

Change

£m unless stated otherwise

FY21e

FY22e

FY23e

FY21e

FY22e

FY21e

FY22e

EPRA earnings

27.5

33.5

35.4

28.0

33.0

-2%

2%

IFRS rent adjustments

(6.4)

(6.3)

(7.0)

(6.3)

(6.6)

Amortisation of loan arrangement fees

0.9

0.9

0.9

0.9

0.9

Adjusted 'cash' earnings

22.0

28.1

29.3

22.6

27.3

-3%

3%

EPRA EPS (p)

8.50

9.56

10.10

8.66

9.42

-2%

2%

Adjusted EPS (p)

6.78

8.02

8.36

6.98

7.79

-3%

3%

DPS (p)

6.41

6.57

6.76

6.41

6.57

0%

0%

EPRA dividend cover

133%

146%

149%

135%

143%

Adjusted earnings dividend cover

106%

122%

124%

109%

119%

EPRA NTA per share

112.3

116.9

121.7

112.6

117.0

0%

0%

Source: Edison Investment Research

Our forecasts assume IHR exercises its option to purchase the 12 homes that constitute the ‘Kingdom’ portfolio8 and an additional £30m of capital deployment by the end of March 2022 (by end-Q122). We assume a 7.25% yield on consideration on this capital commitment, which makes some allowance for the continuing strong investor interest in care home properties, although this may prove to be conservative; management hopes to achieve yields consistent with the c 7.5% historical trend. Adjusting for the acquisitions/investments already announced, our capital deployment assumption is increased c £22m compared with our last published forecast. This reflects IHR’s continuing strong investment pipeline and its increased borrowing capacity. Nonetheless, our forecast borrowings of up to c £160m remains well below total debt facilities of £206m (£230m including a £24m accordion option). We forecast a gross loan to value ratio of 27.7% at end FY22, above the company’s medium-term target of 25% but below its self-imposed ceiling of 30%.

This has no effect on earnings by substituting rental income for the post-tax interest on the loan to Holmes Care.

All rents are inflation linked (predominantly to RPI), capped at around 4.0% with floors at around 2.0%, and we have assumed an average 3.0% increase in FY22/FY23, which based on current levels may prove conservative.9 The company adjusted earnings measure shown in Exhibit 1 excludes non-cash IFRS rent smoothing adjustments (relating to fixed rent increases and lease incentives) and amortisation of loan arrangement fees. Adjusted earnings approximate to cash earnings and a more conservative indicator of dividend paying capacity than EPRA earnings. We forecast 106% cover of dividend by adjusted earnings in FY21 (133% cover on an EPRA earnings basis), increasing to 122% (146% on an EPRA basis) in FY22. Increasing dividend cover demonstrates the strong cash flow emerging from the growing portfolio. Under the company’s progressive dividend formula, linked to rental growth, the 2.5% DPS growth that IHR targeted for FY21 looks back to rent indexation achieved in FY20. The increase in cover that we forecast indicates there is significant scope for future dividend growth beyond the level suggested by this formula, although we have not forecast this.

RPI increased by 7.1% in the 12 months to November 2021 although the Bank of England continues to forecast that inflationary pressures will begin to ease.

We expect property revaluation movements will continue to be driven by rental growth and asset management initiatives in combination with ‘buying well’, contributing to NAV growth.

Exhibit 2: Income statement revaluation movement

£m

FY20

FY21e

FY22e

FY23e

Gross revaluation movement

13.1

12.5

14.3

12.0

Acquisition costs written off

(2.7)

(1.4)

(2.8)

0.0

Net revaluation movement

10.5

11.1

11.5

12.0

IFRS rental smoothing and lease incentive adjustment

(4.9)

(7.1)

(6.3)

(7.0)

Gains/(losses) on revaluation of investment properties as per income statement

5.6

4.0

5.2

5.1

Acquisition costs as % purchase value

3.1%

4.5%

3.3%

n.a.

Gross revaluation as % opening portfolio value

4.1%

3.0%

3.1%

2.1%

Gross revaluation gain per share (p)

4.1

3.6

4.1

3.4

Source: Impact Healthcare REIT historical data, Edison Investment Research forecasts

Valuation

The current year DPS target of 6.41p (+1.9% vs FY20) represents an attractive yield of 5.4%. The shares trade at a c 6% premium to Q321 unaudited NAV per share of 111.82p, which is similar to the average premium since IPO and below the high of c 11%.

IHR aims to provide shareholders with attractive and sustainable returns, primarily in the form of quarterly dividends. DPS has increased each year since IPO, with a clear and progressive dividend policy, targeting growth in line with the inflation-linked rental uplifts received in the preceding financial year. Dividends paid have driven the consistently positive quarterly total returns since IPO in 2017, with aggregate NAV total return (adjusted for dividends paid, but not reinvested) from IPO to end-Q321 of 40.9%, a compound annual return of 7.8%.

In Exhibit 3 we show a summary of the performance and valuation of a group of REITs that we consider to be IHR’s closest peers within the broad and diverse commercial property sector. The group is invested in the primary healthcare, supported housing and care home sectors, all targeting stable, long-term income growth derived from long-lease exposures.

Exhibit 3: Peer group comparison

WAULT
(years)

Price
(p)

Market cap (£m)

P/NTA*
(x)

Yield**
(%)

Target yield*** (%)

Share price performance

1 month

3 months

YTD

12 months

Assura

12

69

2017

1.17

4.2

4.3

-1%

-5%

-11%

-11%

Civitas Social Housing

23

97

595

0.89

5.7

5.7

-1%

8%

-8%

-8%

Home REIT

19

125

699

1.19

2.0

4.4

3%

16%

18%

N/A

Primary Health Properties

12

150

1994

1.30

4.1

4.3

-2%

-3%

-2%

-2%

Target Healthcare

29

116

718

1.04

5.8

5.8

-1%

0%

2%

1%

Triple Point Social Housing

26

96

385

0.90

5.4

5.4

-2%

-1%

-14%

-12%

Average

20

1.08

4.5

5.0

0%

2%

-3%

-6%

Impact Healthcare

19

118

414

1.06

5.4

5.4

-1%

3%

8%

9%

UK property sector index

1,932

-1%

6%

21%

23%

UK equity market index

4,242

2%

4%

15%

11%

Source: Company data, Refinitiv price data at 10 January 2022. Note: *Based on last published EPRA NTA/NAV per share. **Based on trailing 12-month DPS declared. ***Based on company target DPS for current financial year.

Compared with the peer group average, IHR has a clearly higher yield while its P/NAV is slightly below the average. There are several factors that suggest a continuing positive outlook for the shares including a combination of the long weighted average unexpired lease term (WAULT) with no break clauses, fully repairing and insuring leases and upwards-only rents, mostly linked to RPI, which provides considerable visibility over a growing stream of contracted rental income. It also offers considerable protection against inflation at a time when inflation expectations are increasing. The robust tenant performance reported by IHR during the COVID-19 pandemic, with no interruption in rent collections, is a further positive indicator for covenant strength.

Exhibit 4: Financial summary

Year to 31 December (£m)

2017

2018

2019

2020

2021e

2022e

2023e

INCOME STATEMENT

Cash rental income

9.5

13.9

19.1

25.9

30.1

35.1

40.3

Rental income arising from recognising rental premiums, fixed rent uplifts & lease incentives

(0.1)

3.4

4.9

4.9

6.4

6.3

7.0

Net rental income

9.4

17.3

24.0

30.8

36.4

41.4

47.2

Administrative & other expenses

(2.3)

(4.3)

(4.6)

(5.3)

(5.7)

(6.0)

(6.2)

Operating profit before change in fair value of investment properties

7.1

13.0

19.4

25.6

30.7

35.4

41.0

Change in fair value of investment properties

2.4

4.1

9.1

5.6

4.0

5.2

5.1

Gain on disposal

0.0

0.0

0.0

0.2

0.2

0.0

0.0

Operating profit

9.5

17.2

28.5

31.3

34.8

40.6

46.1

Net finance cost

0.0

(0.7)

(2.1)

(2.5)

(3.2)

(1.2)

(5.6)

Profit before taxation

9.5

16.5

26.3

28.8

31.6

39.4

40.5

Tax

(0.0)

0.0

0.0

0.0

0.0

(0.6)

0.0

Profit for the year (IFRS)

9.5

16.5

26.3

28.8

31.6

38.8

40.5

Adjust for:

Change in fair value of investment properties

(2.4)

(4.1)

(9.1)

(5.6)

(4.0)

(5.2)

(5.1)

Gain on disposal

0.0

0.0

0.0

(0.2)

(0.2)

0.0

0.0

Change in fair value of interest rate derivatives

0.0

0.1

0.4

0.1

(0.0)

0.0

0.0

EPRA earnings

7.1

12.4

17.6

23.1

27.5

33.5

35.4

Rental income arising from recognising rental premiums & fixed rent uplifts

0.1

(3.4)

(4.9)

(4.9)

(6.4)

(6.3)

(7.0)

Amortisation of loan arrangement fees

0.0

0.2

0.4

0.7

0.9

0.9

0.9

Non-recurring costs

0.0

0.7

0.2

0.0

0.0

0.0

0.0

Adjusted earnings

7.1

9.9

13.4

18.9

22.0

28.1

29.3

Average number of shares in issue (m)

162.6

192.2

254.0

319.0

323.9

350.6

350.6

Basic & diluted IFRS EPS (p)

5.82

8.57

10.37

9.02

9.77

11.06

11.56

Basic & diluted EPRA EPS (p)

4.35

6.47

6.95

7.25

8.50

9.56

10.10

Basic & diluted adjusted EPS (p)

4.39

5.17

5.26

5.93

6.78

8.02

8.36

Dividend per share (declared)

4.50

6.00

6.17

6.29

6.41

6.57

6.76

EPRA earnings dividend cover

97%

108%

113%

115%

133%

146%

149%

Adjusted earnings dividend cover

98%

86%

85%

94%

106%

122%

124%

BALANCE SHEET

Investment properties

156.2

220.5

310.5

405.7

443.7

541.3

550.4

Other non-current assets

1.7

5.7

10.1

15.9

23.0

29.2

36.2

Non-current assets

157.9

226.2

320.7

421.6

466.7

570.5

586.6

Cash and equivalents

38.4

1.5

47.8

8.0

8.1

4.0

6.3

Other current assets

0.1

0.6

0.6

0.1

38.0

0.5

0.5

Current assets

38.5

2.1

48.3

8.1

46.1

4.5

6.8

Borrowings

0.0

(24.7)

(23.5)

(74.2)

(112.4)

(158.3)

(159.1)

Other non-current liabilities

(1.7)

(1.9)

(1.8)

(2.8)

(2.7)

(2.7)

(2.7)

Non-current liabilities

(1.7)

(26.6)

(25.2)

(77.0)

(115.2)

(161.0)

(161.9)

Borrowings

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Other current liabilities

(1.2)

(3.3)

(3.1)

(3.1)

(3.7)

(4.2)

(4.8)

Current Liabilities

(1.2)

(3.3)

(3.1)

(3.1)

(3.7)

(4.2)

(4.8)

Net assets

193.5

198.3

340.7

349.5

393.9

409.8

426.8

Adjust for derivative financial liability/(asset)

0.0

(0.5)

(0.1)

(0.0)

(0.0)

(0.0)

(0.0)

EPRA net assets

193.5

197.9

340.6

349.5

393.9

409.8

426.8

Period end shares (m)

192.2

192.2

319.0

319.0

350.6

350.6

350.6

IFRS NAV per ordinary share

100.6

103.2

106.8

109.6

112.3

116.9

121.7

EPRA NAV per share

100.6

102.9

106.8

109.6

112.3

116.9

121.7

CASH FLOW

Net cash flow from operating activities

8.2

10.0

14.9

21.0

23.8

29.0

34.6

Purchase of investment properties (including acquisition costs)

(153.3)

(55.1)

(73.4)

(88.5)

(33.1)

(88.3)

0.0

Capital improvements

(0.5)

(3.9)

(8.2)

(1.7)

(2.5)

(4.0)

(4.0)

Other cash flow from investing activities

0.0

0.0

0.1

0.9

(35.8)

40.7

0.0

Net cash flow from investing activities

(153.8)

(58.9)

(81.5)

(89.3)

(71.5)

(51.6)

(4.0)

Issue of ordinary share capital (net of expenses)

189.3

(0.1)

132.2

0.0

34.6

0.0

0.0

(Repayment)/drawdown of loans

0.0

26.0

(0.9)

51.2

38.1

45.0

0.0

Dividends paid

(5.3)

(11.6)

(16.1)

(20.0)

(21.9)

(22.9)

(23.5)

Other cash flow from financing activities

0.0

(2.3)

(2.2)

(2.8)

(3.2)

(3.6)

(4.7)

Net cash flow from financing activities

184.0

12.0

112.9

28.5

47.7

18.5

(28.3)

Net change in cash and equivalents

38.4

(36.9)

46.3

(39.8)

0.1

(4.1)

2.3

Opening cash and equivalents

0.0

38.4

1.5

47.8

8.0

8.1

4.0

Closing cash and equivalents

38.4

1.5

47.8

8.0

8.1

4.0

6.3

Balance sheet debt

0.0

(24.7)

(23.5)

(74.2)

(112.4)

(158.3)

(159.1)

Unamortised loan arrangement costs

0.0

(1.3)

(1.7)

(2.2)

(2.1)

(1.2)

(0.4)

Net cash/(debt)

38.4

(24.5)

22.7

(68.4)

(106.4)

(155.5)

(153.2)

Gross LTV (net debt as % gross assets)

0.0%

11.4%

6.8%

17.8%

22.3%

27.7%

26.9%

Source: Company data, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by Impact Healthcare REIT and prepared and issued by Edison, in consideration of a fee payable by Impact Healthcare REIT. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

General disclaimer and copyright

This report has been commissioned by Impact Healthcare REIT and prepared and issued by Edison, in consideration of a fee payable by Impact Healthcare REIT. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Care REIT

View All

Real Estate

Care REIT — Q4 trading update and increased DPS target

Real Estate

Care REIT — Strong Q324 and accretive growth

Real Estate

Impact Healthcare REIT — Successful turnaround

Real Estate

Impact Healthcare REIT — Visible growth

Latest from the Real Estate sector

View All Real Estate content

Real Estate

Lamda Development — Financial resilience and strategic progress

Real Estate

Edison explains: Europe’s ageing buildings

Real Estate

Trade Estates REIC — New-generation retail assets

Real Estate

Primary Health Properties — Strong earnings growth and strategic progress

Research: Investment Companies

RTW Venture Fund Limited — ‘One-stop shop’ for biotech lifecycle investment

RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from business formations through to investing in much larger listed biotech and medtech companies. RTW is focused on identifying and developing next-generation therapies to significantly improve patients’ lives. Since launch, RTWVF’s number of investments in private companies has accelerated and the manager is very excited by the global opportunities available.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.